FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease. According to Globaldata, it is involved in 2 clinical trials, of which 1 was completed, and 1 is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of FB-102’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FB-102 is expected to reach an annual total of $24 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
FB-102 Overview
Forte Biosciences Overview
Forte Biosciences is a biopharmaceutical company that focuses on autoimmune diseases. Its lead product candidate include FB-102 which is used for the for the treatment of autoimmune diseases such as graft-versus-host disease (GvHD), Vitiligo and Alopecia Areata (AA). GvHD is a complication associated with allogeneic hematopoietic stem cell transplantation. Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color. Alopecia Areata is patches of hair loss occur on the scalp or the body. The Company’s FB-102 program address key pathways in indications with a CD122 antagonist. Forte Biosciences is headquartered in Torrance, California, the US.
The operating loss of the company was US$32.5 million in FY2023, compared to an operating loss of US$13.9 million in FY2022. The net loss of the company was US$31.5 million in FY2023, compared to a net loss of US$13.9 million in FY2022.
For a complete picture of FB-102’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.